Clinical Trial Update: (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating 89Zr-labeled panitumumab with PET/CT for diagnosing metastases in head and neck squamous cell carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma of the Head and Neck
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Panitumumab (89Zr-labeled) (panitumumab)

Snippet

Sponsor: Eben Rosenthal | Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING